Current Cardiac Surgery in South Africa
... venous return to the heart • This should ideally not be longer than 2 minutes but with local hypothermia can be pushed to 4 minutes • It can be repeated if more time is needed, as long as enough time and circulation can be given for recovery of the myocardium ...
... venous return to the heart • This should ideally not be longer than 2 minutes but with local hypothermia can be pushed to 4 minutes • It can be repeated if more time is needed, as long as enough time and circulation can be given for recovery of the myocardium ...
Chronic Postpericardiotomy Syndrome and Cardiac Tamponade
... to become hemodynamically significant and result in cardiac tamponade. Only 1% of their 4,561 patients were found to have echocardiographic evidence of a moderate or large pericardial effusion, and of these 1% of patients, 74% had evidence of cardiac tamponade. They also showed that cardiac tamponad ...
... to become hemodynamically significant and result in cardiac tamponade. Only 1% of their 4,561 patients were found to have echocardiographic evidence of a moderate or large pericardial effusion, and of these 1% of patients, 74% had evidence of cardiac tamponade. They also showed that cardiac tamponad ...
Sleep apnoea in heart failure
... heart failure (CHF), with Cheyne–Stokes respiration (CSR) being the most frequent type of sleepdisordered breathing (SDB) in these patients. Within the present study, the authors sought to assess the prevalence and type of SDB among CHF patients in Germany. A total of 203 CHF patients participated i ...
... heart failure (CHF), with Cheyne–Stokes respiration (CSR) being the most frequent type of sleepdisordered breathing (SDB) in these patients. Within the present study, the authors sought to assess the prevalence and type of SDB among CHF patients in Germany. A total of 203 CHF patients participated i ...
Chapter 9
... 12. A 54-year-old woman carries a diagnosis of mitral regurgitation. She grew up in a remote village in a developing country without access to medical clinics and had several episodes of sore throat as a child. What is the most likely cause of her mitral valve disease? A. Rupture of a necrotic papil ...
... 12. A 54-year-old woman carries a diagnosis of mitral regurgitation. She grew up in a remote village in a developing country without access to medical clinics and had several episodes of sore throat as a child. What is the most likely cause of her mitral valve disease? A. Rupture of a necrotic papil ...
Effect of 5-fluorouracil on sinoatrial node and conduction system of
... of 5-FU. Previously we had observed ECG changes in our patients on 5-FU viz sinus bradycardia, atrial fibrillation. We also found that 5-FU bradycardia might be a hypervagotonia as vagolytics abolished it. This study was undertaken to assess the impact of this commonly used chemotherapeutic agent on ...
... of 5-FU. Previously we had observed ECG changes in our patients on 5-FU viz sinus bradycardia, atrial fibrillation. We also found that 5-FU bradycardia might be a hypervagotonia as vagolytics abolished it. This study was undertaken to assess the impact of this commonly used chemotherapeutic agent on ...
Comments on the 2015 ESC Guidelines for the Management of
... The writing has been simplified in this section and is more precise. The LVEF range of 30% to 40% and the differences between ischemic and nonischemic cardiomyopathy have been eliminated, and the same recommendations have been established for the 2 substrates (LVEF <35%). The new guidelines maintain ...
... The writing has been simplified in this section and is more precise. The LVEF range of 30% to 40% and the differences between ischemic and nonischemic cardiomyopathy have been eliminated, and the same recommendations have been established for the 2 substrates (LVEF <35%). The new guidelines maintain ...
Clinical application of the 22 lead derived electrocardiogram and a
... Clinical application of the 22 lead derived electrocardiogram and a new cardiac electrical biomarker Purpose: The cardiac electrical field is a dipolar 3 lead-vector space but there are 22 leads used in clinical practice including the 12-lead ECG, 3 right heart leads V3R-V6R, 3 posterior leads V7-V9 ...
... Clinical application of the 22 lead derived electrocardiogram and a new cardiac electrical biomarker Purpose: The cardiac electrical field is a dipolar 3 lead-vector space but there are 22 leads used in clinical practice including the 12-lead ECG, 3 right heart leads V3R-V6R, 3 posterior leads V7-V9 ...
S0735109711013441_mmc1
... according to previously described methods (1). The animals were anesthetized (pentobarbital 60 mg/kg), the thorax was opened and a stainless steel hemoclip of 0.6 mm ID was placed on the ascending aorta. Age-matched control animals (sham-operated) underwent the same procedure without placement of th ...
... according to previously described methods (1). The animals were anesthetized (pentobarbital 60 mg/kg), the thorax was opened and a stainless steel hemoclip of 0.6 mm ID was placed on the ascending aorta. Age-matched control animals (sham-operated) underwent the same procedure without placement of th ...
DCM Patient information
... limits and therefore cannot perform as effectively as a pump. The word ‘cardio’ simply means ‘the heart’, ‘myo’ means ‘muscle’, and ‘pathy’ means a disease state. The word 'dilated' in this context means abnormally enlarged. Taken together these terms mean that as the heart muscle becomes enlarged i ...
... limits and therefore cannot perform as effectively as a pump. The word ‘cardio’ simply means ‘the heart’, ‘myo’ means ‘muscle’, and ‘pathy’ means a disease state. The word 'dilated' in this context means abnormally enlarged. Taken together these terms mean that as the heart muscle becomes enlarged i ...
Palpitations - Back to Medical School
... • Symptomatic AF despite adequate rate control • Young symptomatic patients • AF related heart failure • AF secondary to corrected trigger or cause ...
... • Symptomatic AF despite adequate rate control • Young symptomatic patients • AF related heart failure • AF secondary to corrected trigger or cause ...
Abstract
... Health care professionals must be alert to the high prevalence of low adherence to treatment, because Low adherence increases morbidity and medical complications, contributes to poorer quality of life and an overuse of the health care system. Many different factors have an impact on adherence. Howev ...
... Health care professionals must be alert to the high prevalence of low adherence to treatment, because Low adherence increases morbidity and medical complications, contributes to poorer quality of life and an overuse of the health care system. Many different factors have an impact on adherence. Howev ...
Implantable cardioverter-defibrillators: Controlling a
... heart's main pumping chamber (the right ventricle), a biventricular pacemaker stimulates both the right and left ventricles to make the heart beat more efficiently. A special type of ICD — a combined biventricular pacemaker with ICD — can do the same thing. Biventricular pacing is particularly valua ...
... heart's main pumping chamber (the right ventricle), a biventricular pacemaker stimulates both the right and left ventricles to make the heart beat more efficiently. A special type of ICD — a combined biventricular pacemaker with ICD — can do the same thing. Biventricular pacing is particularly valua ...
QRS Duration Criteria to Select Patients for Cardiac
... York Heart Association (NYHA) functional class II-III symptoms, despite optimal medical therapy. According to the same update, CRT may still be considered for patients with QRS intervals between 120 and 150 ms and severe left ventricular dysfunction who have persistent symptoms on medical treatment. ...
... York Heart Association (NYHA) functional class II-III symptoms, despite optimal medical therapy. According to the same update, CRT may still be considered for patients with QRS intervals between 120 and 150 ms and severe left ventricular dysfunction who have persistent symptoms on medical treatment. ...
Atacand (Chronic Heart Failure) - Forecast and Market Analysis to... Brochure
... of entry of Novartis’ LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but ...
... of entry of Novartis’ LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but ...
Beta-blockers for atrial fibrillation
... The study by Kühlkamp et al. (1) represents an important contribution to the literature. In this study, patients with persistent AF were randomized to metoprolol CR/XL or matching placebo. Most patients had been converted with DC shock, although 17.5% converted after a class I antiarrhythmic medica ...
... The study by Kühlkamp et al. (1) represents an important contribution to the literature. In this study, patients with persistent AF were randomized to metoprolol CR/XL or matching placebo. Most patients had been converted with DC shock, although 17.5% converted after a class I antiarrhythmic medica ...
Heart Failure with Preserved Ejection Fraction – Persistent
... exercise 3 days per week for 16 weeks or standard care. The primary outcome of peak exercise oxygen uptake ...
... exercise 3 days per week for 16 weeks or standard care. The primary outcome of peak exercise oxygen uptake ...
Guidelines For Management of Acute Coronary Syndromes
... lab in < 12 hours or if enoxaparin is contraindicated due to renal insufficiency or obesity, initiate unfractionated heparin (UFH) with a bolus of 60 units/kg intravenously (maximum 5000 units) followed by a continuous infusion of 12 units/kg/h (maximum 1000 units/h). Follow guidelines according to ...
... lab in < 12 hours or if enoxaparin is contraindicated due to renal insufficiency or obesity, initiate unfractionated heparin (UFH) with a bolus of 60 units/kg intravenously (maximum 5000 units) followed by a continuous infusion of 12 units/kg/h (maximum 1000 units/h). Follow guidelines according to ...
Pericardial effusion and cardiac neoplasia in dogs
... of pericardial fluid, the pericardium may stretch over time to accommodate the fluid. Eventually, clinical signs will occur, but this phenomenon can lead to relatively large volumes of fluid being present. In our clinic, the current record volume is from a German Shepherd Dog, where we obtained appr ...
... of pericardial fluid, the pericardium may stretch over time to accommodate the fluid. Eventually, clinical signs will occur, but this phenomenon can lead to relatively large volumes of fluid being present. In our clinic, the current record volume is from a German Shepherd Dog, where we obtained appr ...
QRS Duration Criteria to Select Patients for Cardiac
... York Heart Association (NYHA) functional class II-III symptoms, despite optimal medical therapy. According to the same update, CRT may still be considered for patients with QRS intervals between 120 and 150 ms and severe left ventricular dysfunction who have persistent symptoms on medical treatment. ...
... York Heart Association (NYHA) functional class II-III symptoms, despite optimal medical therapy. According to the same update, CRT may still be considered for patients with QRS intervals between 120 and 150 ms and severe left ventricular dysfunction who have persistent symptoms on medical treatment. ...
Twelve-lead
... Infarction (Acute)—abnormal Q wave, ST segment may be elevated and T wave may be inverted Infarction (Age Unknown)—abnormal Q wave, ST segment and T wave returned to normal ...
... Infarction (Acute)—abnormal Q wave, ST segment may be elevated and T wave may be inverted Infarction (Age Unknown)—abnormal Q wave, ST segment and T wave returned to normal ...
Lipoma of the right atrium
... these tumors have a subendocardial origin, 25% have an intramyocardial origin (affecting most frequently the left ventricle, right atrium, and the interatrial septum), and the remaining 25% have a pericardial origin.5 Although they may be asymptomatic for years, they may present with cardiac symptom ...
... these tumors have a subendocardial origin, 25% have an intramyocardial origin (affecting most frequently the left ventricle, right atrium, and the interatrial septum), and the remaining 25% have a pericardial origin.5 Although they may be asymptomatic for years, they may present with cardiac symptom ...
MED SURGE CARDIAC 4, VALVE DISORDERS
... Mitral regurgitation involves blood flowing back from the left ventricle into the left atrium during systole. Often, edges of mitral valve leaflets do not close completely during systole because leaflets and chordae tendineae have thickened and fibrosed, resulting in their contraction. The most comm ...
... Mitral regurgitation involves blood flowing back from the left ventricle into the left atrium during systole. Often, edges of mitral valve leaflets do not close completely during systole because leaflets and chordae tendineae have thickened and fibrosed, resulting in their contraction. The most comm ...
Comments on the 2015 ESC Guidelines for the Management of
... The writing has been simplified in this section and is more precise. The LVEF range of 30% to 40% and the differences between ischemic and nonischemic cardiomyopathy have been eliminated, and the same recommendations have been established for the 2 substrates (LVEF <35%). The new guidelines maintain ...
... The writing has been simplified in this section and is more precise. The LVEF range of 30% to 40% and the differences between ischemic and nonischemic cardiomyopathy have been eliminated, and the same recommendations have been established for the 2 substrates (LVEF <35%). The new guidelines maintain ...
Prognostic Indicators for Recurrent Thrombotic
... The incidence and predictors of cardiac death or MI (both STEMI and NSTEMI) were the main outcomes of interest. Secondary outcomes were target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis. Cardiac death was also distinguished as sudden and non-sudden. M ...
... The incidence and predictors of cardiac death or MI (both STEMI and NSTEMI) were the main outcomes of interest. Secondary outcomes were target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis. Cardiac death was also distinguished as sudden and non-sudden. M ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.